Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Account Payables
Amounts the company owes suppliers for goods and services received.
Septerna, Inc.NASDAQ: SEPN
Account Payables · Q3 FY2026 · quarter ended Sep 2026
Account payables rises 86.7% from a year ago
Account payables stood at $6.96M at the end of Q3 FY2026, up 86.7% from a year earlier and up 75.4% from the prior quarter. Over 3 fiscal years it compounded at +49.6% a year.
Context
- Account payables amounted to 1.1% of total assets at the end of Q3 FY2026, up 0.5 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +86.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 10.28M USD
- Year-over-year change
- +221.3%
- 3-year CAGR
- +49.6%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.28M | +221.3% |
| FY2024 | 2024-12-31 | 3.2M | +21.4% |
| FY2023 | 2023-12-31 | 2.64M | -14.1% |
| FY2022 | 2022-12-31 | 3.07M | — |
Account Payables vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 account payables of $6.96M is the 3rd highest of the 7 companies compared; the peer median is $6.81M.
- Its year-over-year change of +86.7% is the highest of 6, against a peer median of +62.8%.
- Account payables amounts to 1.1% of total assets for SEPN, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | Jun 2026 | $19.2M | — | — | 1.6% |
| Jun 2026 | $11.13M | +23.8% | +32.1% | 0.8% | |
SEPNSepterna, Inc. | Sep 2026 | $6.96M | +86.7% | +49.6% | 1.1% |
| Mar 2026 | $6.82M | +62.8% | -22.8% | 6.9% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $6.81M | +80.6% | +45.0% | 1.4% |
| Mar 2026 | $4.61M | -40.1% | -22.1% | 9.9% | |
| Mar 2026 | $4.01M | +66.9% | +4.2% | 1.0% | |
| Peer median (excluding SEPN) | $6.81M | +62.8% | +4.2% | 1.5% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.